Get MindMed Updates:
NEW YORK, Nov. 2, 2020 /PRNewswire/ — MindMed (NEO: MMED,OTCQB: MMEDF), the leading psychedelic medicine biotech company in partnership with University Hospital Basel’s Liechti Lab announces the completion and publication of a Phase 1 study on the acute dose dependent effects of LSD. The completed Phase 1 study will help MindMed in dose-finding and the planning of future Phase 2 clinical trials of LSD in patients with anxiety disorders and other medical conditions.
Specifically, the Phase 1 study measured LSD dose-dependently induced subjective responses starting at microdoses (25 ug) up to experiential doses (200 ug). Maximal good drug effects were reached at a 100 ug dose. However, an experiential dose of 200 ug LSD was shown to induce greater ego dissolution than a lesser 100 ug dose. Ego-dissolution is thought to be one of the key therapeutic potentials of the psychedelic experience and psychedelic assisted therapy process.
MindMed’s Co-Founder and Co-CEO, J.R. Rahn, commented on the results, “We see this now completed study as an important stepping stone with highly relevant data to support Project Lucy as the team identifies optimal dose levels of LSD to test in the intended Phase 2b trial of an anxiety disorder. As COVID-19 continues to compound society’s prevalence of anxiety disorders globally, MindMed is pushing ahead with full vigor on the planning and design of Project Lucy.”
The study was published in Neuropsychopharmacology, which is an international scientific journal and the official publication of the American College of Neuropsychopharmacology (ACNP)
The publication can be found here : https://www.nature.com/articles/s41386-020-00883-6#Sec20
Link to original article here: https://www.prnewswire.com/news-releases/mindmed-announces-the-completion-of-phase-1-study-measuring-dosing-effects-of-lsd-301164518.html
MindMed Bolsters Management Team, Appoints Peter Mack PhD as Vice President of Pharmaceutical Development
MindMed Announces Project Angie, Targeting the Treatment of Pain with Psychedelics
MindMed Begins Trading on Nasdaq